ART OF MEDICINE 2017

 

IMMUNE PROFILE OF HIGH – GRADE DIFFUSE ASTROCYTIC TUMORS AND ITS INFLUENCE ON TUMOR PROGRESSION

 

T.N. Chertenko, I.I. Yakovtsova

          Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

  

Abstract

Abstract. Immunotherapeutic treatment has shown great efficiency in the therapy of different malignancies. The central nervous system (CNS) was considered an immunological privileged organ, but new data has changed this dogma. There is an evidence for permeability of the blood-brain barrier (BBB) for immune cells under conditions of tumor growth, such as in gliomas. Arming the immune system to mount a strong anti-tumor response in high grade gliomas is an aim of many research projects therefore investigation of immune profiles of gliomas is very important nowadays.

Objective. The study of expression of CD3, CD4, CD8 and CD68 markers in high-grade gliomas.

Methods. The research is based on histological and immunohistochemical investigation of 30 biopsies of patients with newly diagnosed high-grade gliomas in the period from 2011 to 2016. All biopsy samples were taken from Kharkiv regional clinical hospital and Kharkiv city clinical hospital №7. Immunoreactivity was defined as a proportion of a labeled cells in hot spot areas of tumor that calculated in 5 fields of view (x400): high (3), more than 30% of cells positive for given markers in hot spot areas, moderate (2), less than 30% of cells positive for given markers in hot spot areas, low (1), only single cells are positive for given markers in hot spot areas, negative reaction (0).

Results. We compared histological samples and clinical data of 15 patients with newly diagnosed high-grade gliomas, which relapsed during the 1-st year after surgery, and samples of 15 patients, who did not have relapse or death during the 1-st year after surgery. According to our data only high or middle expression of CD68 can be count as an independent marker of pour prognosis (Fisher’s exact test = 0,037, p  <0,05). Independent expression of CD3, CD4 and CD8 markers did not show any prognostic value, but we found that solid tumors with immune profile CD3(2-3)/CD8(0-1) give statistically more relapses as other types of high grade gliomas (Fisher’s exact test = 0,04981, р < 0,05). In addition, we found a beneficial immune profile that was a marker of a better prognosis. It was СD3 (0-1)/CD4 (2-3)/ CD8 (2-3) profile (Fisher’s exact test Fisher’s exact test = 0,01869, р < 0,05).

Conclusions. The present data show that combination of СD3(0-1)/CD4(2-3)/CD8(2-3) is a predictor of better clinical outcome in high-grade glioma patients (Fisher’s exact test = 0,01869, р < 0,05), and combination of high or middle CD3 expression with low CD8 expression in solid high-grade gliomas is associated with higher rate of relapses during the 1-st year after surgery (Fisher’s exact test =0,04981, р < 0,05). CD68 high or middle expression can be used as an independent factor that tells about unfavorable prognosis for patients with malignant gliomas (Fisher’s exact test = 0,037, p <0,05).

 

Keywords: glioblastoma, anaplastic astrocytoma, immune profile of GBM, tumor-infiltrating cells, IHC in gliomas.

 

Full text: PDF (Rus)

References
  1. Justyna Kmiecik. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with immunosuppressive at the systemic level prolonged survival in glioblastoma patients despite integrated mechanisms in the tumor microenvironment and at the systemic level. / Justyna Kmiecik, Aurélie Poli. // J of Neuroimmunology. – 2013. – №264. – P. 71–83.
  2. Ohgaki H. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. / Ohgaki H, Kleihues P. // J Neuropathol Exp Neurol. – 2005. – №64. – P. 479–489.
  3. Ohgaki H. Genetic pathways to glioblastoma: a population-based study. / Ohgaki H, Dessen P, Jourde B. // Cancer Res. – 2004. – №64. – P. 6892–6899.
  4. Neha Kamran. Immunosuppressive myeloid cells’blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy. / Neha Kamran, Padma Kadiyala, Meghna Saxena. // Molecular Therapy. – 2017. – Vol. 25. №1.
  5. Haouraa Mostafa. Immune phenotypes predict survival in patients with glioblastoma multiforme. [Електронний ресурс] / Haouraa Mostafa, Andrej Pala, Josef Högel // Journal of Hematology & Oncology. – 2016. – Режим доступу до ресурсу: DOI 10.1186/s13045-016-0272-3.
  6. Judy Choi. Glioblastoma cells induce differential glutamatergic gene expressions in human tumor-associated microglia/ macrophagesand monocyte-derived macrophages. / Judy Choi, Beate Stradmann-Bellinghausen. // Cancer Biology & Therapy. – 2015. – №16. – P. 1205–1213.
  7. Immunohistological study of mononuclear cell infiltrate in malignant gliomas. / Rossi ML, Hughes JT, Esiri MM etc.]. // Acta Neuropathol. – 1987. – №74. – P. 269–277.
  8. Tadej Strojnik. Prognostic Impact of CD68 and Kallikrein 6 in Human Glioma / Tadej Strojnik, Rajko Kavalar. // Anticancer research. – 2009. – №29. – P. 3269–3280.
  9. Morris CS. Immunocytochemical study of macrophages and microglial cells and extracellular matrix components in human CNS disease: gliomas. / Morris CS, Esiri MM. // J Neurol Sci. – 1991. – №101. – P. 47–58.
  10. Roggendorf W. Distribution and characterization of microglia/macrophages in human brain tumours / Roggendorf W, Strupp S, Paulus W. // Acta Neuropathol. – 1996. – №92. – P. 288–293.
  11. Louis DN. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summery. / Louis DN, Perry A. // Acta Neuropathol. – 2016. – №131. – P. 803–820.
  12. Diagnostic Techniques in Hematological Malignancies / In W. Erber. – Cambridge: Cambridge University Press, 2010. – P. 133.
  13. Jenni M. Penttila. Expansion of a Novel Pulmonary CD3- CD4+ CD8+ Cell Population in Mice during Chlamydia pneumoniae Infection. / Jenni M. Penttila, Reijo Pyhala. // Infection and immunity. – 1998. – Vol. 66.№7. – P. 3290–3294.
  14. Lou Yongli. Function of PD-L1 in antitumor immunity of glioma cells. / Lou Yongli, Shi Jin. // Saudi Journal of Biological Sciences. – 2017. – №24. – P. 803–807.
  15. Kyu Sang Lee. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma [Електронний ресурс] / Kyu Sang Lee, Kyoungyul Lee // Journal of Neuro-Oncology – Режим доступу до ресурсу: https:// doi.org/10.1007/s11060-017-2675-6.
  16. Choi SJ. The radiologic features of cystic versus noncystic glioblastoma multiforme as significant prognostic factors. / Choi SJ, Hwang HY. // J Korean Soc Radiol.. – 2010. – №63. – P. 299–306.
  17. Gurvinder Kaur. A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival / Gurvinder Kaur, Bloch O. A. // J Neurosurg. – 2011. – №115. – P. 754–759.
  18. WHO Classification of Tumours of the Central Nervous System. / Louis D.N., Ohgaki H, Wiestler O.D etc.]. – Lyon: IARC, 2007.
  19. Hans-Anton Lehr. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. / Hans-Anton Lehr, David A. Mankoff. // Journal of Histochemistry & Cytochemistry. – 1997. – Vol.45. №11. – P. 1559–1565.